# A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

> **NCT05726864** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Elicio Therapeutics** · enrollment: 158 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Colorectal Cancer
- KRAS G12D
- KRAS G12R
- KRAS G12V
- KRAS G12A
- KRAS G12C
- KRAS G12S
- KRAS G13D
- NRAS G12D
- NRAS G12R
- NRAS G12V
- NRAS G12C
- NRAS G12S

## Interventions

- **DRUG:** ELI-002 7P

## Key facts

- **NCT ID:** NCT05726864
- **Lead sponsor:** Elicio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-14
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05726864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05726864, "A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05726864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*